Recently Featured

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

May 25, 2026
Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, showcasing the efficacy of Novo Nordisk’s CagriSema in improving body composition among adults with obesity. This trial is pivotal as it not only highlights the potential of CagriSema as a therapeutic option but also reinforces the growing focus on body composition as a critical…

As Trump Arrives in China, Big Pharma CEOs Are Notably Absent

May 25, 2026
As President Trump lands in Beijing, a significant absence is felt among his business delegation—leaders from the pharmaceutical industry. This notable lack of representation raises questions about the current state of U.S.-China relations, particularly in the context of the ongoing trade tensions and regulatory challenges facing the pharma sector. The absence of Big Pharma CEOs…

Lakefront Biotherapeutics Aims for Turnaround from Galapagos Transformation

May 25, 2026
CHICAGO — Lakefront Biotherapeutics, formerly known as Galapagos, is strategically positioned in a 22nd-floor office overlooking the Chicago Riverwalk, a central location in the Midwest’s corporate landscape. This transformation marks a significant pivot for the company, which aims to revitalize its portfolio and enhance its market presence amidst evolving industry challenges. The rebranding effort comes…

Merck KGaA Looks to M&A to Bolster Its ‘Rather Slim’ Pipeline

May 24, 2026
Under the leadership of new CEO Kai Beckmann, Merck KGaA has signaled a strategic shift towards mergers and acquisitions as a means to enhance its early- to mid-stage pharmaceutical pipeline. In its recent first quarter results, the company acknowledged that its current pipeline is ‘rather slim,’ prompting a need for external growth opportunities to drive…

Ongoing Cases